@article{664829932df44ccf99ee329a17aaa101,
title = "Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis",
abstract = "The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabetes complications and cardiovascular risk. This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options.",
keywords = "ADA consensus statement, Algorithm, Cardiovascular risk, EASD consensus statement, Glucose-lowering therapy, Hyperglycaemia, Type 2 diabetes",
author = "G. Schernthaner and Barnett, {A. H.} and Betteridge, {D. J.} and R. Carmena and A. Ceriello and B. Charbonnel and M. Hanefeld and R. Lehmann and Malecki, {M. T.} and R. Nesto and V. Pirags and A. Scheen and J. Seufert and A. Sjoh{\"o}lm and A. Tsatsoulis and R. DeFronzo",
note = "Funding Information: M. T. Malecki has received lecture fees from Berlin-Chemie, Bioton, Eli Lilly, NovoNordisk, Roche and Servier, and grant support from Eli Lilly. R. Nesto has received lecture fees from GSK and sanofi-aventis. A. Scheen has received lecture fees from AstraZeneca/BMS, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, NovoNordisk, sanofi-aventis and Takeda. J. Seufert has received lecture fees from AstraZeneca/BMS, Bayer, Berlin Chemie, Eli Lilly, GlaxoSmith-Kline, Lifescan, Merck Sharp & Dohme, Novartis, NovoNordisk, Pfizer, sanofi-aventis and Takeda. R. DeFronzo has received lecture fees from Amylin, BMS, Eli Lilly, ISIS, Merck, Novartis and Takeda. The remaining authors declare that there is no duality of interest associated with this manuscript.",
year = "2010",
month = jul,
doi = "10.1007/s00125-010-1702-3",
language = "English (US)",
volume = "53",
pages = "1258--1269",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "7",
}